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Arterial hypertension (AH) is a common problem during the treat-. 
ment of patients with renal anaemia, on periodic haemodialysis 
treated with recombinat human erythropoetin. There is so far no ex­
planation for this.We decided, along with a clinical trial of rhEPO 
(Boehringer-Mannheim), to investigate the level of some parameters 
which are known to take part in the regulation of blood pressure, 
namely: plasma activity of angiotensin-converting enzyme ACE) and 
kallikrein-kinin system (KKS). A total of 22 patients with CRF treated 
with PHD were investigated: 11 controls and 11 treated with rhEPO. 
All of them, aged above 18 years, had hematocrit below 28%, and 
PHD duration over six months. rhEPO administration was subcuta­
neous, 3 times a week, 10 min before the beginning of every haemo­
dialysis treatment, with initial dosage of 20 U/kg body weight. The 
dose was increased, if after 6 weeks the target hematocrit of 30-35 
vol% was not acchieved.Plasma ACE activity was determined spec-
trophotometrically after Chushman and Cheung (1971) and Lieber-
mann (1975), modified by Chankova (1987), with Bz-Gly-His-Leu as 
a substrate being used. KKS activity was determined after J . Vitt at 
al. (1978). Student's test was used for statistical evaluations. 
Table 1. Changes of plasma angiotensin-converting enzyme ac­
tivity in patients on PHD and on rhEPO treatment (U/l) (p - NS) 
Patients on PHD without rhEPO Patients on PHD and rhEPO 




11 8 10 10 
















The table 1 shows activity of ACE in the two groups patients on 
PHD-controls and treated with rhEPO. The difference between ACE 
activity in the two groups of patients is not significant. These results 
show, too, that the alterations are due to haemodialysis per se, while 
rhEPO treatment does not alter ACE activity. The results of KKS in-
vestigation show significant increase both of plasma prekallikrein 
(table 2) and kallikrein (table 3), in both groups of patients. 
Table 2. Plasma prekallikrein in patients on PHD and rhEPO 
treatment (U/l) (* p <0,05) 
Treated with rhEPO Without rhEPO treatment 
Before After 6 After 12 Before After 6 After 12 
treatment months months treatment months months 
x 268 439 315 258 471 374 
SD ±93 ±107* ± 7 9 ± 9 6 ± 202* ±135 
Table 3. Plasma kallikrein in patients on PHD and rhEPO treat-
ment (U/l) (p<0,05) 
Treated with rhEPO 
Before After 6 After 12 
treatment months months 
Without rhEPO treatment 
Before After 6 After 12 










± 7 3 
These alternations should again be explained by the haemodia-
lysis treatment, because they are found both in the control group of 
p patients on PHD, as well as in those, treated with rhEPO. We relate 
the activation of ACE and KKS to the extracorporeal blood purifica-
tion, including the remaining blood in the dialysis filters and their 
double and triple reuse. We conclude that: 1. The treatment with 
rhEPO does not change the plasma ACE activity. 2. Plasma prekal-
likrein and kallikrein are activated in patients on PHD. No significant 
difference is observed between treated and non-treated with rhEPO. 
